RxDoctor Payments Data

Bruce van Vranken, MD

Family Medicine · Laguna Woods, CANPI 1093742173

Payments from drug & device makers

$8,699in general payments, 2019–2025

Across 503 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$368
  • Takeda Pharmaceuticals U.S.A., Inc.$336
  • Novo Nordisk$306
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,685100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,699 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$39,119
Medicare patients
119
Services billed
759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$76,815
EliquisApixaban76$63,984
XareltoRivaroxaban33$32,814
RybelsusSemaglutide13$26,552
LinzessLinaclotide19$26,022
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$20,163
FarxigaDapagliflozin Propanediol14$16,338
MounjaroTirzepatide13$15,511
Emgality PenGalcanezumab-Gnlm12$8,251
MyrbetriqMirabegron12$8,101
TrintellixVortioxetine Hydrobromide14$7,072
Wixela InhubFluticasone Propion/Salmeterol14$5,354
SymbicortBudesonide/Formoterol Fumarate17$3,821
Testosterone Cypionate58$3,493
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$3,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$368$76,81553 claims
PfizerEliquis$85$63,98476 claims
Johnson & JohnsonXarelto$240$32,81433 claims
AbbVieLinzess, Armour Thyroid$1,624$27,13136 claims
Novo NordiskRybelsus$306$26,55213 claims
GSKTrelegy Ellipta$286$20,16319 claims
AstraZenecaFarxiga, Symbicort$1,021$20,15831 claims
Lilly USA, LLCMounjaro$1,115$15,51113 claims
Astellas Pharma US IncMyrbetriq$132$8,10112 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$336$7,07214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Laguna Woods

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →